Group II metabotropic glutamate receptors and schizophrenia

被引：49

作者：

Moreno, Jose L. ^{[1
,3
]}

Sealfon, Stuart C. ^{[2
,4
]}

Gonzalez-Maeso, Javier ^{[1
,2
,3
]}

机构：

[1] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA

[2] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA

[3] Mt Sinai Sch Med, Div Basic Neurosci, New York, NY 10029 USA

[4] Mt Sinai Sch Med, Ctr Translat Syst Biol, New York, NY 10029 USA

来源：

CELLULAR AND MOLECULAR LIFE SCIENCES | 2009年 / 66卷 / 23期

关键词：

Schizophrenia; Antipsychotics; G protein-coupled receptors (GPCR); Serotonin receptors; 5-HT2A; Metabotropic glutamate receptors; mGluR2; mGluR3; PROTEIN-COUPLED RECEPTOR; TYPE-3 GENE GRM3; DORSOLATERAL PREFRONTAL CORTEX; CATECHOL-O-METHYLTRANSFERASE; ATYPICAL ANTIPSYCHOTICS; WORKING-MEMORY; OBSTETRIC COMPLICATIONS; ACTIVATION MECHANISM; MOLECULAR-MECHANISMS; HALLUCINOGENIC DRUG;

D O I：

10.1007/s00018-009-0130-3

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Schizophrenia is one of the most common mental illnesses, with hereditary and environmental factors important for its etiology. All antipsychotics have in common a high affinity for monoaminergic receptors. Whereas hallucinations and delusions usually respond to typical (haloperidol-like) and atypical (clozapine-like) monoaminergic antipsychotics, their efficacy in improving negative symptoms and cognitive deficits remains inadequate. In addition, devastating side effects are a common characteristic of monoaminergic antipsychotics. Recent biochemical, preclinical and clinical findings support group II metabotropic glutamate receptors (mGluR2 and mGluR3) as a new approach to treat schizophrenia. This paper reviews the status of general knowledge of mGluR2 and mGluR3 in the psychopharmacology, genetics and neuropathology of schizophrenia.

引用

页码：3777 / 3785

页数：9

共 50 条

[11] Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia
Chaki, Shigeyuki
EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 639 (1-3) : 59 - 66
[12] The possible involvement of metabotropic glutamate receptors in schizophrenia
Krivoy, Amir
Fischel, Tsvi
Weizman, Abraham
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (06) : 395 - 405
[13] Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
Chaki, Shigeyuki
Hikichi, Hirohiko
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (02) : 94 - 102
[14] Metabotropic glutamate receptors as therapeutic targets for schizophrenia
Vinson, Paige N.
Conn, P. Jeffrey
NEUROPHARMACOLOGY, 2012, 62 (03) : 1461 - 1472
[15] The role of group II metabotropic glutamate receptors in the modulation of seizure activity
Klodziñska, A
Chojnacka-Wójcik, E
Pilc, A
NEUROPHARMACOLOGY, 1999, 38 (10) : A24 - A24
[16] Expression of group II metabotropic glutamate receptors in rat gustatory papillae
Toyono, Takashi
Kataoka, Shinji
Seta, Yuji
Shigemoto, Ryuichi
Toyoshima, Kuniaki
CELL AND TISSUE RESEARCH, 2007, 328 (01) : 57 - 63
[17] Roles of group II metabotropic glutamate receptors in modulation of seizure activity
Klodzinska, A
Bijak, M
Chojnacka-Wójcik, E
Kroczka, B
Swiader, M
Czuczwar, SJ
Pilc, A
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 361 (03) : 283 - 288
[18] RADIOIODINATION OF BENZODIAZEPINE DERIVATIVES AS LIGANDS FOR GROUP II METABOTROPIC GLUTAMATE RECEPTORS
Koren, A. O.
Da Costa, H.
Cosgrove, K. P.
Staley, J. K.
Amici, L. A.
Bois, F.
Baldwin, R. M.
Tamagnan, G. D.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2005, 48 : S89 - S89
[19] Folic acid as an antagonist for group II metabotropic glutamate receptors.
Saitoh, T
Ishida, M
Shinozaki, H
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R141 - R141
[20] Structures of the extracellular regions of the group II/III metabotropic glutamate receptors
Muto, Takanori
Tsuchiya, Daisuke
Morikawa, Kosuke
Jingami, Hisato
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (10) : 3759 - 3764

← 1 2 3 4 5 →